188345-25-7

Basic information

• Product Name: 3,4-DIFLUORO-N-METHOXY-N-METHYLBENZAMIDE
• Synonyms: 3,4-DIFLUORO-N-METHOXY-N-METHYLBENZAMIDE;3,4-Difluoro-N-methyl-N-methoxybenzamide
• CAS NO: 188345-25-7
• Molecular Formula: C₉H₉F₂NO₂
• Molecular Weight: 201.17
• Mol File: 188345-25-7.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 315.1 °C at 760 mmHg
• Flash Point: 144.4 °C
• Appearance: /
• Density: 1.261 g/cm³
• Vapor Pressure: 0.000447mmHg at 25°C
• Refractive Index: 1.493
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3,4-DIFLUORO-N-METHOXY-N-METHYLBENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DIFLUORO-N-METHOXY-N-METHYLBENZAMIDE(188345-25-7)
• EPA Substance Registry System: 3,4-DIFLUORO-N-METHOXY-N-METHYLBENZAMIDE(188345-25-7)

Safety Data

• Hazardous Substances Data: 188345-25-7(Hazardous Substances Data)

Usage

General Description

3,4-Difluoro-N-methoxy-N-methylbenzamide is a chemical compound with the molecular formula C9H9F2NO2. Lack of widespread information suggests that it is rarely studied and its applications are likely specific and limited. It contains elements such as carbon, hydrogen, fluorine, nitrogen, and oxygen. Important aspects to consider about this compound would be its physical and chemical properties, such as its melting point, boiling point, density, and potential for reactivity. However, this information isn't readily available, reinforcing the notion that this is a specialized chemical with narrow uses. Overall, safety and handling procedures for this chemical, like any other, must be strictly observed to mitigate potential risks or hazards.

InChI:InChI=1/C9H9F2NO2/c1-12(14-2)9(13)6-3-4-7(10)8(11)5-6/h3-5H,1-2H3

Upstream product

• 455-86-7 3,4-Difluorobenzoic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 76903-88-3 3,4-difluorobenzoyl chloride 

Downstream Products

• 1017598-61-6 (3,4-difluorophenyl){4-[(tetrahydro-2H-pyran-2-yloxy)methyl]phenyl}methanone 
• 677320-17-1 2-(2-t-Butoxycarbonylaminopyridin-4-yl)-1-(3,4-difluorophenyl)ethan-1-one 
• 312758-44-4 C₁₁H₁₃F₂NO 
• 369-33-5 3',4'-difluoroacetophenone 
• 844878-99-5 (4-bromophenyl)-(3,4-difluorophenyl)-methanone 
• 1189175-69-6 (3,4-difluorophenyl)[5-({[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl)-2-pyridinyl]methanone 
• 244262-69-9 allyl-[1-(3,4-difluoro-phenyl)-vinyl]-carbamic acid ethyl ester 
• 244263-36-3 Allyl-[1-(3,4-difluoro-phenyl)-eth-(E)-ylidene]-amine 

Relevant articles and documents

SUBSTITUTED 3,4,12,12A-TETRAHYDRO-1H-[1,4]OXAZINO[3,4-C]PYRIDO[2,1-F][1,2,4]TRIAZINE-6,8-DIONE, PHARMACEUTICAL COMPOSITION, AND METHODS FOR PREPARING AND USING SAME

Influenza is an acute infectious respiratory disease caused by the influenza virus. It is part of the group of Acute Respiratory Viral Infections (ARVI). It occasionally spreads in the form of epidemics and pandemics. Currently, more than 2000 variants of the influenza virus differing in the antigen spectrum have been identified. Given that influenza is a serious threat to public health (worldwide, these annual epidemics lead to 3-5 million cases of severe illness, millions of hospitalizations, and up to 650,000 deaths), it seems appropriate to search for new anti-influenza drugs with improved characteristics. The inventors surprisingly found out that the previously unknown substituted 3,4,12,12a-tetrahydro-1 H-[1,4] oxazino[3,4-c]pyrido[2,1-f] [1,2,4]triazine-6,8-dione of general formula 1, its stereoisomer, their prodrug, pharmaceutically acceptable salt, solvate, hydrate, and a crystalline or polycrystalline form thereof are effective agents for prophylaxis and treatment of viral diseases, including influenza where R1 is (6,7-difluoro-5,10-dihydrothieno[3,2-c][2]benzothiepin-10-yl, (7,8-difluoro-4,9-dihydrothieno[2,23-c][2]benzothiepin-4-yl, (3,4-difluorophenyl)(phenyl)methyl, (3,4-difluorophenyl)(2-methylsulfanylphenyl)methyl, diphenylmethyl, bis(4-fluorophenyl)-methyl; R2 is hydrogen or a protective group selected from a series comprising (C1-C3 alkyl) oxycarbonyloxy, {[(C1-C3 alkyl)oxycarbonyl]-oxy}methoxy, {[2-(C1-C3 alkyl) oxyethoxy]carbonyl}oxy, ({[(1R)-2-[(C1-C3alkyl)oxy]-1-methylethoxy}carbonyl)oxy, {[(3S)-ethoxyfuran-3-yloxy]-carbonyl}oxy, [(ethoxy-2H-pyran-4-yloxy)carbonyl]oxy,{[(1-acetylazetidine)-3-yloxy]carbonyl}oxy, {[(C1-C3alkyl) oxycarbonyl] -oxy}methoxy, ({[2-(C1-C3 alkyl)oxyethoxy]carbonyl}oxy) methoxy.

Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors

A series of 3-aryl-3-azolylpropan-1-amines was prepared and screened for its capability of inhibiting monoamine reuptake. Analogs with nanomolar potency, good human in vitro microsomal stability, and low drug-drug interaction potential were described. In

DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR

[Problems] To provide an antagonist of a melanin-concentrating hormone receptor, which is useful as a medicine for a central nervous system disease, a cardiovascular disease or a metabolic disease. [Means for Solving Problems] The antagonist comprises, as an active ingredient, a compound represented by the formula (I) wherein R1a and R1b independently represent a hydrogen atom or a C1-6 alkyl group; R2a, R2b, R3a and R3b independently represent a hydrogen atom, a C1-6 alkyl group, or the like; Y represents H or —OH; Z represents —OR8, or the like; R8 represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, or the like; R9a and R9b independently represent a hydrogen atom, a C1-6 alkyl group, or the like; Ar1 represents an aromatic carbon ring group, or an aromatic heteroring group; Ar2 represents a group produced by removing two hydrogen atoms from an aromatic carbon ring, or the like; and the ring group A represents an unsaturated heteroring group.